CSPG4 and hematologic disorder: Based on its structure, distribution, and functions, NG2/CSPG4 has been suggested to promote tumor progression by multiple mechanisms and represents, to date, a powerful target for chimeric antigen receptor-based T-cell (CAR-T) immunotherapy of solid and hematological malignancies [27,28,29].